title: Treatment of pediatric hodgkin lymphoma.
abstract: We are increasingly successful in the treatment of Hodgkin lymphoma. Current risk adapted trials seek to maintain the excellent efficacy of older therapies, while simultaneously limiting their late toxicities. Current management of early stage/favorable disease involves the use of two to four cycles of tailored chemotherapy, often followed by low-dose, involved field radiation. Those with intermediate and advanced stage disease require more intense chemotherapy and radiation regimens. Functional imaging using [(18)F]-2 fluoro-D-2-deoxyglucose is increasingly used to determine complete vs. partial response and to detect relapse. Given the success of primary therapy, retrieval of patients remains a highly individualized challenge. The majority of children failing combined-modality treatment undergo high-dose chemotherapy followed by autologous hematopoietic stem cell rescue, oftentimes with consolidative radiotherapy.
authors.affiliation: Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Olson
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Donaldson
mesh_terms: D002648:Child; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans